ReviewAntibiotics (Basel, Switzerland)2023
Epidemiology of
Review in Antibiotics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06318104 (Efficacy and Safety of a Triple Eradication Scheme for Helicobacter Pylori Based on Amoxicillin 1g + Clarithromycin 500 mg and Tegoprazan 50 mg vs Amoxicillin 1g + Clarithromycin 500 mg and Esomeprazole 40 mg Twice a Day for 14 Days), which is not on this map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Safety of a Triple Eradication Scheme for Helicobacter Pylori Based on Amoxicillin 1g + Clarithromycin 500 mg and Tegoprazan 50 mg vs Amoxicillin 1g + Clarithromycin 500 mg and Esomeprazole 40 mg Twice a Day for 14 Days
Who cites it
16 citing papers in PubMed.
- Levofloxacin versus moxifloxacin in nitazoxanide-based quadruple therapy as a first-line treatment for Helicobacter pylori infection: NILE, a randomized, comparative, multicenter study.Scientific reports · 2026Trial
- The functional and catalytic landscape of urease reveals a conserved target againstGut microbes · 2026Article
- Antimicrobial Resistance Patterns and Predictors inMicroorganisms · 2026Article
- Clinical impact of high-dose esomeprazole-amoxicillin dual therapy as rescue treatment for Helicobacter pylori infection: a meta-analysis of randomized controlled trials.Gut pathogens · 2026Review
- Impact of kimura-takemoto atrophy classification on first-lineFrontiers in medicine · 2026Article
- Probiotics as Adjuvants to StandardMicroorganisms · 2025Review
- Review
- Chitosan-Based Schiff Bases (CSBs) and Their Metal Complexes: Promising Antimicrobial Agents.Molecules (Basel, Switzerland) · 2025Review
- Vonoprazan and amoxicillin dual therapy versus bismuth-based therapy forProceedings (Baylor University. Medical Center) · 2025Article
- Dysregulated macrophage immunity inFrontiers in immunology · 2025Review
- Whole-genome sequencing analyses and antibiotic resistance situation of 48 Helicobacter pylori strains isolated in Zhejiang, China.Gut pathogens · 2024Article
- The Challenges of Treating aJournal of clinical medicine · 2024Review
- Optimization ofInternational journal of molecular sciences · 2024Article
- [Impact of primary duodenogastric reflux andZhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2024Article
- Concomitant and Bismuth Quadruple Therapy forAntibiotics (Basel, Switzerland) · 2024Article
- Influence of Source Materials, Concentration, Gastric Digestion, and Encapsulation on the Bioactive Response of Brassicaceae-Derived Samples againstMicroorganisms · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.